Insight Molecular Diagnostics Inc.
IMDX | NASDAQ
$4.20
+$0.19 (+4.74%)
Sep 22, 2026, 2:16 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | -4.55 | -0.51 | -0.67 | -0.32 | -3.01 | -5.23 |
PEG Ratio | 0.07 | -0.02 | 0.01 | -0.01 | -0.05 | -1.06 |
PS Ratio | 56.37 | 16.54 | 12.73 | 37.13 | 87.79 | 128.69 |
PB Ratio | -7.26 | -2.53 | 0.93 | 0.90 | 2.96 | 4.67 |
P/FCF Ratio | -9.01 | -1.47 | -0.81 | -0.71 | -5.05 | -5.75 |
P/OCF Ratio | -10.30 | -1.50 | -0.82 | -0.78 | -5.37 | -6.02 |
OCF/S Ratio | -547.08 | -1.1K | -1.55K | -4.76K | -1.64K | -2.14K |
Debt / Equity Ratio | -0.11 | -0.30 | 0.14 | 0.09 | 0.09 | 0.26 |
Quick Ratio | 1.23 | 1.56 | 1.49 | 2.11 | 2.75 | 1.03 |
Current Ratio | 1.27 | 1.62 | 1.49 | 2.11 | 2.77 | 1.03 |
Asset Turnover | 0.16 | 0.05 | 0.02 | 0.01 | 0.01 | 0.02 |
Interest Coverage | -280.53 | -726.68 | -483.38 | -216.83 | -257.06 | -117.90 |
Return on Equity | 159.62% | 494.24% | -135.73% | -184.12% | -98.28% | -89.39% |
Return on Assets | -194.99% | -172.92% | -37.09% | -72.84% | -40.17% | -54.01% |
Return on Invested Capital | -197.43% | -209.76% | -36.77% | -20.27% | -30.03% | -57.92% |
Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | 4.69% | 39.34% | 27.48% | -1.88% | 64.60% | -52.55% |
Net Profit Margin | -1.24K% | -3.23K% | -1.85K% | -7.61K% | -2.92K% | -2.46K% |
Pretax Profit Margin | -1.24K% | -3.23K% | -1.65K% | -1.94K% | -2.41K% | -2.56K% |
Operating Profit Margin | -754.08% | -3.25K% | -1.67K% | -1.88K% | -2.44K% | -2.44K% |
FCF Margin | -625.62% | -1.13K% | -1.57K% | -5.21K% | -1.74K% | -2.24K% |
EBITDA Margin | -1.18K% | -3.14K% | -1.54K% | -1.39K% | -2.2K% | -2.51K% |
Add to Watchlist
Select watchlists to add or remove IMDX